Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma

Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma

BackgroundLutetium 177 (177Lu) - DOTATATE is a form of peptide receptor radionuclide therapy (PRRT) utilized in the treatment of neuroendocrine tumors. Data on 177Lu-DOTATATE-induced thyroid dysfunction is limited.Case DescriptionA 29-year-old male with SDHB positive metastatic paraganglioma enrolle...

Full description

Bibliographic Details
Main Authors: Sriram Gubbi, Mohammad Al-Jundi, Jaydira Del Rivero, Abhishek Jha, Marianne Knue, Joy Zou, Baris Turkbey, Jorge Amilcar Carrasquillo, Emily Lin, Karel Pacak, Joanna Klubo-Gwiezdzinska, Frank I-Kai Lin
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Endocrinology
Subjects:
DOTATATE
Lutathera
hypothyroidism
peptide receptor radionuclide therapy
paraganglioma
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2020.587065/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2020.587065/full

Similar Items